Abstract | OBJECTIVES: MATERIALS AND METHODS: Retrospective review of patients with Stage III/IV HNSCC who had surgery followed by adjuvant chemoradiation therapy at Mayo Clinic, Rochester. HPV and/or p16 status was available for all oropharynx patients. RESULTS: 104 Patients (51 high-dose, 53 weekly) were analyzed. The 3-year overall survival was 84% and 75% for patients who received high dose and weekly cisplatin, respectively (p=0.30). The 3-year recurrence free survival was 71% and 74% in the high dose and weekly cisplatin group, respectively (p=0.95). Patients with HPV/p16-positive oropharynx cancer who received adjuvant chemoradiation therapy with high-dose and weekly cisplatin had three-year overall survival rates of 91% and 86% (p=0.56), and 3-year recurrence free survival of 84% and 82% (p=0.93). Extracapsular extension did not affect prognosis in either group. CONCLUSIONS: No significant survival difference was seen between patients with locally advanced HNSCC treated with adjuvant chemoradiation therapy with high-dose or weekly cisplatin, although there was a trend for improved survival with high-dose cisplatin. Weekly cisplatin in the adjuvant setting may be a better treatment for patients with HPV-positive oropharynx cancer to preserve survival and minimize toxicity.
|
Authors | Jessica L Geiger, Ahmed F Lazim, Francis J Walsh, Robert L Foote, Eric J Moore, Scott H Okuno, Kerry D Olsen, Jan L Kasperbauer, Daniel L Price, Yolanda I Garces, Daniel J Ma, Michelle A Neben-Wittich, Julian R Molina, Joaquin J Garcia, Katharine A R Price |
Journal | Oral oncology
(Oral Oncol)
Vol. 50
Issue 4
Pg. 311-8
(Apr 2014)
ISSN: 1879-0593 [Electronic] England |
PMID | 24467937
(Publication Type: Journal Article, Research Support, N.I.H., Extramural)
|
Copyright | Copyright © 2014 Elsevier Ltd. All rights reserved. |
Chemical References |
- Antineoplastic Agents
- Cisplatin
|
Topics |
- Antineoplastic Agents
(therapeutic use)
- Cisplatin
(therapeutic use)
- Dose-Response Relationship, Drug
- Female
- Head and Neck Neoplasms
(drug therapy, radiotherapy, surgery, virology)
- Humans
- Male
- Papillomaviridae
(isolation & purification)
|